Coherus BioSciences Financials
| CHRS Stock | USD 1.04 0.04 4.00% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.23 | 1.29 |
|
|
Investors should never underestimate Coherus BioSciences' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Coherus BioSciences' cash flow, debt, and profitability to make informed and accurate decisions about investing in Coherus BioSciences.
Net Income |
|
Coherus | Select Account or Indicator |
Understanding current and past Coherus BioSciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Coherus BioSciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Coherus BioSciences' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Coherus BioSciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Coherus BioSciences. Check Coherus BioSciences' Beneish M Score to see the likelihood of Coherus BioSciences' management manipulating its earnings.
Coherus BioSciences Stock Summary
Coherus BioSciences competes with Assembly Biosciences, Spero Therapeutics, Achilles Therapeutics, Instil Bio, and NextCure. Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Coherus Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 368 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US19249H1032 |
| CUSIP | 19249H103 |
| Location | California; U.S.A |
| Business Address | 333 Twin Dolphin |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.coherus.com |
| Phone | 650 649 3530 |
| Currency | USD - US Dollar |
Coherus BioSciences Key Financial Ratios
| Return On Equity | -16.57 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | (0.09) % | ||||
| Price To Sales | 0.38 X | ||||
| Revenue | 257.24 M |
Coherus BioSciences Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 841.6M | 679.3M | 480.8M | 629.6M | 724.0M | 362.5M | |
| Other Current Liab | 127.3M | 145.7M | 122.9M | 294.4M | 338.6M | 355.5M | |
| Other Liab | 102K | 75.1M | 94.3M | 3.5M | 4.0M | 3.8M | |
| Net Debt | (137.1M) | (8.9M) | 407.5M | 378.0M | 434.6M | 456.4M | |
| Retained Earnings | (762.8M) | (1.0B) | (1.3B) | (1.6B) | (1.4B) | (1.4B) | |
| Accounts Payable | 15.2M | 16.2M | 11.5M | 35.2M | 40.5M | 42.5M | |
| Cash | 541.2M | 417.2M | 63.5M | 102.9M | 118.3M | 182.4M | |
| Other Assets | 45.9M | 60.5M | 45.9M | 64.2M | 73.8M | 77.5M | |
| Net Receivables | 157.0M | 123.0M | 110.0M | 260.5M | 299.6M | 314.6M | |
| Inventory | 92.2M | 93.3M | 115.1M | 62.6M | 72.0M | 41.2M | |
| Other Current Assets | 25.0M | 24.5M | 40.8M | 34.8M | 40.0M | 42.0M | |
| Total Liab | 560.7M | 581.6M | 618.3M | 823.0M | 946.5M | 993.8M | |
| Total Current Assets | 790.4M | 633.5M | 416.7M | 475.6M | 547.0M | 311.1M | |
| Short Term Debt | 3.1M | 3.5M | 4.3M | 2.1M | 1.9M | 1.8M | |
| Net Tangible Assets | 101.7M | 277.4M | 97.7M | (143.3M) | (164.9M) | (156.6M) | |
| Long Term Debt | 377.4M | 408.3M | 225.6M | 473.4M | 544.4M | 571.6M | |
| Capital Surpluse | 1.0B | 1.0B | 1.1B | 1.2B | 1.4B | 900.6M |
Coherus BioSciences Key Income Statement Accounts
The reason investors look at the income statement is to determine what Coherus BioSciences' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 21.2M | 23.0M | 32.5M | 40.5M | 46.6M | 49.0M | |
| Total Revenue | 475.8M | 326.6M | 211.0M | 257.2M | 295.8M | 172.9M | |
| Gross Profit | 438.2M | 269.0M | 141.0M | 94.5M | 108.6M | 141.2M | |
| Operating Income | 156.3M | (263.9M) | (256.9M) | (203.2M) | (182.9M) | (173.7M) | |
| Ebit | 156.9M | (266.3M) | (259.3M) | (197.7M) | (178.0M) | (186.9M) | |
| Research Development | 142.8M | 363.1M | 199.4M | 109.4M | 125.9M | 164.4M | |
| Ebitda | 161.8M | (260.7M) | (255.6M) | (193.9M) | (174.5M) | (183.3M) | |
| Cost Of Revenue | 37.7M | 57.6M | 70.1M | 162.8M | 146.5M | 83.5M | |
| Income Before Tax | 135.7M | (287.1M) | (291.8M) | (238.3M) | (214.4M) | (203.7M) | |
| Net Income | 132.2M | (306.3M) | (326.6M) | (237.9M) | (214.1M) | (224.8M) | |
| Income Tax Expense | 3.5M | 19.2M | 34.9M | (380K) | (437K) | (415.2K) | |
| Net Interest Income | (21.2M) | (23.0M) | (32.5M) | (40.5M) | (36.5M) | (34.7M) | |
| Tax Provision | 3.5M | 1.1M | 0.0 | (380K) | (342K) | (324.9K) |
Coherus BioSciences Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (36.2M) | (6.3M) | (47.3M) | (46.7M) | (42.1M) | (40.0M) | |
| Change In Cash | 363.7M | (124.0M) | (353.6M) | 39.4M | 35.4M | 37.2M | |
| Free Cash Flow | 147.1M | (38.7M) | (243.2M) | (175.2M) | (157.7M) | (149.8M) | |
| Depreciation | 2.9M | 3.5M | 3.7M | 3.8M | 4.4M | 2.7M | |
| Other Non Cash Items | 6.0M | 143.1M | 75.5M | 52.9M | 60.9M | 30.8M | |
| Capital Expenditures | 7.1M | 1.3M | 2.0M | 286K | 328.9K | 312.5K | |
| Net Income | 132.2M | (287.1M) | (291.8M) | (237.9M) | (214.1M) | (203.4M) | |
| End Period Cash Flow | 541.6M | 417.6M | 64.0M | 103.3M | 118.8M | 182.6M | |
| Investments | 155K | (1.1M) | (127.4M) | 144.6M | 166.3M | 174.7M | |
| Change To Netincome | 34.2M | 38.2M | 249.7M | 83.0M | 95.4M | 68.6M |
Coherus Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Coherus BioSciences's current stock value. Our valuation model uses many indicators to compare Coherus BioSciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Coherus BioSciences competition to find correlations between indicators driving Coherus BioSciences's intrinsic value. More Info.Coherus BioSciences is rated below average in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, Coherus BioSciences' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Coherus BioSciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Coherus BioSciences Systematic Risk
Coherus BioSciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Coherus BioSciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Coherus BioSciences correlated with the market. If Beta is less than 0 Coherus BioSciences generally moves in the opposite direction as compared to the market. If Coherus BioSciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Coherus BioSciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Coherus BioSciences is generally in the same direction as the market. If Beta > 1 Coherus BioSciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Coherus BioSciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Coherus BioSciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Coherus BioSciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
At this time, Coherus BioSciences' Price Earnings To Growth Ratio is comparatively stable compared to the past year.
Coherus BioSciences March 8, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Coherus BioSciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Coherus BioSciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Coherus BioSciences based on widely used predictive technical indicators. In general, we focus on analyzing Coherus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Coherus BioSciences's daily price indicators and compare them against related drivers.
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 37.41 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 12.3 |
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.